BSLN Basilea Pharmaceutica AG

86.27USD72.70 CHF · SWX+1.68%Mkt Cap: 1.07B USDP/E: 18.13

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intrav…

Institutional holders10 on file

Key Statistics

Company
Market Cap1.07B USD
Enterprise Value963.65M USD
Revenue (TTM)293.59M USD
Gross Profit229.09M USD
Net Income (TTM)47.75M USD
Revenue/Share23.86 USD
Last Price86.27 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees200
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0011432447
Valuation
P/E (Trailing)18.13
P/E (Forward)12.63
PEG-0.08
EV/EBITDA13.33
EV/Revenue3.28
P/S3.64
P/B5.55
EPS (TTM)4.76 USD
EPS (Forward)6.83 USD
52W Range
54.4190% of range89.95
52W High89.95 USD
52W Low54.41 USD
Profitability
Gross Margin83.08%
Oper. Margin24.20%
EBITDA Margin24.62%
Profit Margin17.32%
ROE31.45%
ROA14.27%
ROIC78.83%
ROCE22.14%
Growth
Revenue Growth14.50%
Earnings Growth64.40%
Cash Flow & Leverage
Operating CF73.68M USD
CapEx (TTM)3.40M USD
FCF Margin15.19%
FCF Yield4.17%
Net Debt-106.33M USD
Net Debt/EBITDA-1.47
Net Debt/FCF-2.38
Balance Sheet
Debt/Equity0.70
Current Ratio6.60
Quick Ratio5.81
Book Value/Sh15.53 USD
Cash/Share16.56 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 11, 2013
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)118.21 USD
Upside (mean)+37.0%
Target Range79.50 USD – 149.63 USD
79.50+37.0% to mean149.63
# Analysts5
Ownership
Shares Out.12.39M
Float11.31M
Insiders0.62%
Institutions30.16%
Technical
SMA 5081.73 (+5.5%)
SMA 20068.79 (+25.4%)
Beta0.32
S&P 52W Chg12.00%
Avg Vol (30d)31.78K
Avg Vol (10d)24.30K
Technical Indicators
RSI (14)58.2
MACD1.0966
MACD Signal1.2296
MACD Hist.-0.1329
BB Upper88.14 USD
BB Middle84.95 USD
BB Lower81.76 USD
BB Width7.52%
ATR (14)2.503 USD
Vol Ratio (20d)0.75x

About Basilea Pharmaceutica (SWX: BSLN)

›

Basilea Pharmaceutica (SWX: BSLN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 200 employees.

The shares were at 72.70 CHF on 19 November 2026, up 57.7% over 52 weeks. Its 52-week range is 45.85 CHF to 75.80 CHF: the price is 4.1% below the high and 58.6% above the low.

At a market capitalisation of 901.05M CHF, it trades at 18.1 times trailing earnings and 12.6 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 46% for BSLN.

Basilea Pharmaceutica reports return on equity of 31.5%, an operating margin of 24.2% and revenue up 14.5% year over year.

It holds more cash than debt, a net cash position of 89.61M CHF. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 99.62 CHF is 37.0% above the current price. The next earnings report is expected on 16 February 2027.